ANI Pharmaceuticals, Inc. (ANIP)
USD 69.61
(0.59%)
USD 69.61
(0.59%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 46.97 Million USD | 297.61% |
| 2022 | -25.06 Million USD | 22.91% |
| 2021 | -32.51 Million USD | -102.39% |
| 2020 | -16.06 Million USD | -198.24% |
| 2019 | 16.35 Million USD | -53.76% |
| 2018 | 35.35 Million USD | 24.82% |
| 2017 | 28.32 Million USD | 41.09% |
| 2016 | 20.07 Million USD | -38.6% |
| 2015 | 32.7 Million USD | 63.45% |
| 2014 | 20 Million USD | 2127.84% |
| 2013 | 898 Thousand USD | 103.88% |
| 2012 | -23.17 Million USD | 54.5% |
| 2011 | -50.92 Million USD | -16.78% |
| 2010 | -43.6 Million USD | -13.49% |
| 2009 | -38.42 Million USD | -113.31% |
| 2008 | -18.01 Million USD | -107.54% |
| 2007 | -8.67 Million USD | -352.33% |
| 2006 | 3.43 Million USD | 136.98% |
| 2005 | -9.3 Million USD | 24.17% |
| 2004 | -12.26 Million USD | -102.89% |
| 2003 | -6.04 Million USD | -58.66% |
| 2002 | -3.81 Million USD | -36.79% |
| 2001 | -2.78 Million USD | 23.99% |
| 2000 | -3.66 Million USD | -128.35% |
| 1999 | -1.6 Million USD | 39.65% |
| 1998 | -2.65 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 15.05 Million USD | 72.83% |
| 2024 Q2 | 5.52 Million USD | -63.28% |
| 2023 FY | 49.52 Million USD | 297.61% |
| 2023 Q1 | 9.89 Million USD | 99.09% |
| 2023 Q2 | 12.4 Million USD | 25.34% |
| 2023 Q3 | 17.94 Million USD | 44.72% |
| 2023 Q4 | 8.71 Million USD | -51.47% |
| 2022 Q4 | 4.97 Million USD | 628.16% |
| 2022 FY | -25.06 Million USD | 22.91% |
| 2022 Q3 | -941 Thousand USD | 91.09% |
| 2022 Q1 | -19.19 Million USD | 19.09% |
| 2022 Q2 | -10.56 Million USD | 44.98% |
| 2021 Q1 | 3.04 Million USD | 819.94% |
| 2021 Q2 | -15.55 Million USD | -610.77% |
| 2021 FY | -32.51 Million USD | -102.39% |
| 2021 Q3 | -3.56 Million USD | 77.1% |
| 2021 Q4 | -23.72 Million USD | -566.0% |
| 2020 Q2 | -11.3 Million USD | -44.19% |
| 2020 Q1 | -7.84 Million USD | -67.89% |
| 2020 Q3 | 2.8 Million USD | 124.78% |
| 2020 FY | -16.06 Million USD | -198.24% |
| 2020 Q4 | 331 Thousand USD | -88.19% |
| 2019 FY | 16.35 Million USD | -53.76% |
| 2019 Q4 | -4.67 Million USD | -163.74% |
| 2019 Q2 | 9.29 Million USD | 111.09% |
| 2019 Q3 | 7.32 Million USD | -21.14% |
| 2019 Q1 | 4.4 Million USD | -61.54% |
| 2018 Q1 | 6.53 Million USD | -11.41% |
| 2018 Q3 | 10.11 Million USD | 39.25% |
| 2018 Q2 | 7.26 Million USD | 11.11% |
| 2018 FY | 35.35 Million USD | 24.82% |
| 2018 Q4 | 11.44 Million USD | 13.16% |
| 2017 Q4 | 7.37 Million USD | -20.92% |
| 2017 FY | 28.32 Million USD | 41.09% |
| 2017 Q3 | 9.33 Million USD | 33.41% |
| 2017 Q2 | 6.99 Million USD | 51.22% |
| 2017 Q1 | 4.62 Million USD | 256.32% |
| 2016 Q2 | 5.19 Million USD | -8.33% |
| 2016 Q1 | 5.66 Million USD | -9.6% |
| 2016 FY | 20.07 Million USD | -38.6% |
| 2016 Q4 | 1.29 Million USD | -83.61% |
| 2016 Q3 | 7.92 Million USD | 52.5% |
| 2015 Q1 | 9.56 Million USD | -11.19% |
| 2015 Q2 | 8.41 Million USD | -12.05% |
| 2015 FY | 32.7 Million USD | 63.45% |
| 2015 Q3 | 8.45 Million USD | 0.44% |
| 2015 Q4 | 6.26 Million USD | -25.83% |
| 2014 Q3 | 8.19 Million USD | 433.29% |
| 2014 Q2 | -2.46 Million USD | -170.39% |
| 2014 Q4 | 10.77 Million USD | 31.38% |
| 2014 Q1 | 3.49 Million USD | 1.01% |
| 2014 FY | 20 Million USD | 2127.84% |
| 2013 Q1 | -2.94 Million USD | 18.98% |
| 2013 FY | 898 Thousand USD | 103.88% |
| 2013 Q4 | 3.46 Million USD | 327.01% |
| 2013 Q3 | 810.29 Thousand USD | 121.47% |
| 2013 Q2 | -3.77 Million USD | -28.29% |
| 2012 Q4 | -3.63 Million USD | 31.92% |
| 2012 Q2 | 108.78 Thousand USD | 101.57% |
| 2012 Q1 | -6.93 Million USD | 32.68% |
| 2012 FY | -23.17 Million USD | 54.5% |
| 2012 Q3 | -5.33 Million USD | -5004.36% |
| 2011 Q3 | -13.02 Million USD | 0.28% |
| 2011 Q1 | -15.8 Million USD | -19.46% |
| 2011 FY | -50.92 Million USD | -16.78% |
| 2011 Q4 | -10.29 Million USD | 20.97% |
| 2011 Q2 | -13.06 Million USD | 17.33% |
| 2010 Q2 | -10.24 Million USD | -14.3% |
| 2010 FY | -43.6 Million USD | -13.49% |
| 2010 Q1 | -8.95 Million USD | 37.8% |
| 2010 Q4 | -13.22 Million USD | -19.65% |
| 2010 Q3 | -11.05 Million USD | -7.98% |
| 2009 Q1 | -4.06 Million USD | -118.53% |
| 2009 FY | -38.42 Million USD | -113.31% |
| 2009 Q3 | -6.37 Million USD | -37.87% |
| 2009 Q2 | -4.62 Million USD | -13.75% |
| 2009 Q4 | -14.4 Million USD | -126.12% |
| 2008 Q3 | -6.69 Million USD | -21.35% |
| 2008 Q2 | -5.51 Million USD | -38.97% |
| 2008 Q1 | -3.96 Million USD | -97.11% |
| 2008 FY | -18.01 Million USD | -107.54% |
| 2008 Q4 | -1.85 Million USD | 72.22% |
| 2007 Q2 | -2.63 Million USD | -39.3% |
| 2007 Q3 | -2.14 Million USD | 18.38% |
| 2007 Q1 | -1.88 Million USD | -119.02% |
| 2007 Q4 | -2.01 Million USD | 6.25% |
| 2007 FY | -8.67 Million USD | -352.33% |
| 2006 Q1 | -3.32 Million USD | -85.46% |
| 2006 FY | 3.43 Million USD | 136.98% |
| 2006 Q3 | -867.54 Thousand USD | 62.2% |
| 2006 Q4 | 9.92 Million USD | 1244.27% |
| 2006 Q2 | -2.29 Million USD | 30.97% |
| 2005 Q2 | -2.68 Million USD | 6.45% |
| 2005 Q4 | -1.79 Million USD | 8.43% |
| 2005 Q1 | -2.86 Million USD | 31.87% |
| 2005 Q3 | -1.95 Million USD | 27.05% |
| 2005 FY | -9.3 Million USD | 24.17% |
| 2004 Q2 | -2.62 Million USD | -6.36% |
| 2004 Q3 | -2.95 Million USD | -12.34% |
| 2004 Q4 | -4.21 Million USD | -42.51% |
| 2004 FY | -12.26 Million USD | -102.89% |
| 2004 Q1 | -2.47 Million USD | -41.59% |
| 2003 Q1 | -1.24 Million USD | -202.55% |
| 2003 FY | -6.04 Million USD | -58.66% |
| 2003 Q4 | -1.74 Million USD | -21.36% |
| 2003 Q3 | -1.43 Million USD | 11.59% |
| 2003 Q2 | -1.62 Million USD | -30.76% |
| 2002 FY | -3.81 Million USD | -36.79% |
| 2002 Q4 | -411.39 Thousand USD | 48.64% |
| 2002 Q3 | -801 Thousand USD | 46.67% |
| 2002 Q2 | -1.5 Million USD | -36.19% |
| 2002 Q1 | -1.1 Million USD | 23.43% |
| 2001 Q1 | -722 Thousand USD | 25.73% |
| 2001 Q4 | -1.44 Million USD | -603.03% |
| 2001 FY | -2.78 Million USD | 23.99% |
| 2001 Q3 | 286.33 Thousand USD | 133.34% |
| 2001 Q2 | -858.91 Thousand USD | -18.96% |
| 2000 Q4 | -972.1 Thousand USD | -42.76% |
| 2000 Q1 | -516.2 Thousand USD | 0.0% |
| 2000 FY | -3.66 Million USD | -128.35% |
| 2000 Q3 | -680.92 Thousand USD | 54.47% |
| 2000 Q2 | -1.49 Million USD | -189.75% |
| 1999 FY | -1.6 Million USD | 39.65% |
| 1999 Q2 | -326.16 Thousand USD | 0.0% |
| 1998 FY | -2.65 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 71.867% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | 1967.473% |
| Embecta Corp. | 221.5 Million USD | 78.794% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 46.426% |
| PainReform Ltd. | -9.58 Million USD | 590.098% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 1081.569% |
| SCYNEXIS, Inc. | 72.66 Million USD | 35.363% |
| Journey Medical Corporation | -2.07 Million USD | 2365.847% |
| Safety Shot Inc | -12.18 Million USD | 485.509% |
| Alpha Teknova, Inc. | -35.56 Million USD | 232.078% |
| Bright Green Corporation | -8.89 Million USD | 628.276% |
| Procaps Group, S.A. | 38.97 Million USD | -20.522% |
| Alvotech | -354.86 Million USD | 113.236% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | 411.025% |
| Cosmos Health Inc. | -21.83 Million USD | 315.155% |
| Dynavax Technologies Corporation | -37.02 Million USD | 226.853% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 130.194% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 129.471% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 1081.569% |
| Theratechnologies Inc. | -10.62 Million USD | 541.997% |
| Harrow Health, Inc. | 580 Thousand USD | -7998.448% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | 1099.17% |
| Biofrontera Inc. | -22.67 Million USD | 307.131% |
| DURECT Corporation | -36.88 Million USD | 227.348% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 991.459% |
| Cronos Group Inc. | -81.37 Million USD | 157.721% |
| OptiNose, Inc. | -22.74 Million USD | 306.484% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 77.53% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 219.968% |
| RedHill Biopharma Ltd. | 12.63 Million USD | -271.841% |
| Organogenesis Holdings Inc. | 12.52 Million USD | -275.018% |
| Guardion Health Sciences, Inc. | -4.33 Million USD | 1183.2% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | 856.277% |
| Radius Health, Inc. | -3.92 Million USD | 1296.713% |
| Universe Pharmaceuticals INC | -3.52 Million USD | 1431.84% |
| ProPhase Labs, Inc. | -21.61 Million USD | 317.328% |
| Phibro Animal Health Corporation | 53.31 Million USD | 11.899% |
| Procaps Group S.A. | 52.32 Million USD | 10.23% |
| TherapeuticsMD, Inc. | -8.52 Million USD | 651.109% |
| Viatris Inc. | 766.2 Million USD | 93.87% |
| Rockwell Medical, Inc. | -6.67 Million USD | 804.213% |
| Aytu BioPharma, Inc. | -5.25 Million USD | 994.005% |
| SIGA Technologies, Inc. | 83.62 Million USD | 43.829% |
| Tilray Brands, Inc. | -174.74 Million USD | 126.88% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | -403.387% |
| Shineco, Inc. | -17.06 Million USD | 375.234% |
| PetIQ, Inc. | 60.01 Million USD | 21.735% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | 1091.634% |
| Incannex Healthcare Limited | -30.04 Million USD | 256.356% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 81.279% |
| Alimera Sciences, Inc. | -1.47 Million USD | 3293.134% |
| Silver Spike Investment Corp. | 7.34 Million USD | -539.922% |
| Assertio Holdings, Inc. | -243.53 Million USD | 119.287% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | 897.148% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | 444.935% |
| Clever Leaves Holdings Inc. | -15.59 Million USD | 401.212% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 334.269% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 134.074% |
| Hempacco Co., Inc. | -8.81 Million USD | 633.018% |
| Talphera, Inc. | -16.88 Million USD | 378.116% |
| Alvotech | -354.86 Million USD | 113.236% |
| Eagle Pharmaceuticals, Inc. | 53.45 Million USD | 12.128% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 87.119% |
| Currenc Group, Inc. | -6.64 Million USD | 806.779% |
| Kamada Ltd. | 10.06 Million USD | -366.723% |
| Indivior PLC | -4 Million USD | 1274.275% |
| Evoke Pharma, Inc. | -7.43 Million USD | 732.105% |
| Flora Growth Corp. | -50.35 Million USD | 193.282% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 334.269% |
| Evolus, Inc. | -49.23 Million USD | 195.406% |
| HUTCHMED (China) Limited | 18.37 Million USD | -155.624% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 76.155% |
| Akanda Corp. | -10.05 Million USD | 567.309% |